Understanding ARDS-associated fibroproliferation

Intensive Care Medicine

Volumn 41, Issue 3, 2015, Pages 517-520

  Meduri, Gianfranco Umberto ^a   Eltorky, Mahmoud A ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID RECEPTOR ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; AUTACOID;

ADULT RESPIRATORY DISTRESS SYNDROME; ARTICLE; DISEASE ASSOCIATION; ENDOTHELIUM; EPITHELIUM; GAS EXCHANGE; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; INTERSTITIUM; LEUKOCYTE ACTIVATION; LUNG ALVEOLUS CELL; LUNG BIOPSY; LUNG DISEASE; LUNG FIBROPROLIFERATION; BRONCHOALVEOLAR LAVAGE FLUID; DISEASE COURSE; IMMUNOLOGY; INNATE IMMUNITY; LUNG FIBROSIS; MORTALITY; PATHOLOGY;

BRONCHOALVEOLAR LAVAGE FLUID; DISEASE PROGRESSION; HUMANS; IMMUNITY, INNATE; INFLAMMATION MEDIATORS; NF-KAPPA B; PULMONARY FIBROSIS; RESPIRATORY DISTRESS SYNDROME, ADULT;

EID: 84925541043     PISSN: 03424642     EISSN: 14321238     Source Type: Journal    
DOI: 10.1007/s00134-014-3613-0     Document Type: Article

References (20)

1. Ashbaugh DG, Bigelow DB, Petty TL, Levine BE (1967) Acute respiratory distress in adults. Lancet 2:319–323
2. Kumar V, Abbas A, Fausto N, Aster J (2010) Cellular response to stress and toxic insults: adaptation, injury and, death. In: Kumar V, Abbas A, Fausto N, Aster J (eds) Robbins and Cotran Pathologic basis of disease. W.B. Saunders, Philadelphia, pp 3–42
3. Meduri GU, Annane D, Chrousos GP, Marik PE, Sinclair SE (2009) Activation and regulation of systemic inflammation in ARDS: rationale for prolonged glucocorticoid therapy. Chest 136:1631–1643
4. Friedman R, Hughes AL (2002) Molecular evolution of the NF-kappaB signaling system. Immunogenetics 53:964–974
5. Meduri GU, Muthiah MP, Carratu P, Eltorky M, Chrousos GP (2005) Nuclear factor-kappaB- and glucocorticoid receptor alpha-mediated mechanisms in the regulation of systemic and pulmonary inflammation during sepsis and acute respiratory distress syndrome. Evidence for inflammation-induced target tissue resistance to glucocorticoids. Neuroimmunomodulation 12:321–338
6. Meduri GU, Eltorky M, Winer-Muram HT (1995) The fibroproliferative phase of late adult respiratory distress syndrome. Semin Respir Infect 10:154–175
7. Katzenstein AL, Bloor CM, Leibow AA (1976) Diffuse alveolar damage—the role of oxygen, shock, and related factors. A review. Am J Pathol 85:209–228
8. Thille AW, Esteban A, Fernandez-Segoviano P, Rodriguez JM, Aramburu JA, Vargas-Errazuriz P, Martin-Pellicer A, Lorente JA, Frutos-Vivar F (2013) Chronology of histological lesions in acute respiratory distress syndrome with diffuse alveolar damage: a prospective cohort study of clinical autopsies. Lancet Respir Med 1:395–401
9. Ichikado K, Muranaka H, Gushima Y, Kotani T, Nader HM, Fujimoto K, Johkoh T, Iwamoto N, Kawamura K, Nagano J, Fukuda K, Hirata N, Yoshinaga T, Ichiyasu H, Tsumura S, Kohrogi H, Kawaguchi A, Yoshioka M, Sakuma T, Suga M (2012) Fibroproliferative changes on high-resolution CT in the acute respiratory distress syndrome predict mortality and ventilator dependency: a prospective observational cohort study. BMJ open 2:e000545
10. Meduri GU, Tolley EA, Chinn A, Stentz F, Postlethwaite A (1998) Procollagen types I and III aminoterminal propeptide levels during acute respiratory distress syndrome and in response to methylprednisolone treatment. Am J Respir Crit Care Med 158:1432–1441
11. Meduri GU (1996) The role of the host defence response in the progression and outcome of ARDS: pathophysiological correlations and response to glucocorticoid treatment. Eur Respir J 9:2650–2670
12. Cordier J-F, Peyrol S, Loire R (1994) Bronchiolitis obliterans organizing pneumonia as a model of inflammatory lung disease. In: Epler GR (ed) Diseases of the Bronchioles. Raven Press Ltd, New York, pp 313–345
13. Burnham EL, Janssen WJ, Riches DW, Moss M, Downey GP (2014) The fibroproliferative response in acute respiratory distress syndrome: mechanisms and clinical significance. Eur Respir J 43:276–285
14. Conway Morris A, Kefala K, Wilkinson TS, Dhaliwal K, Farrell L, Walsh T, Mackenzie SJ, Reid H, Davidson DJ, Haslett C, Rossi AG, Sallenave JM, Simpson AJ (2009) C5a mediates peripheral blood neutrophil dysfunction in critically ill patients. Am J Respir Crit Care Med 180:19–28
15. Meduri GU (2002) Clinical review: a paradigm shift: the bidirectional effect of inflammation on bacterial growth. Clinical implications for patients with acute respiratory distress syndrome. Crit Care 6:24–29
16. Serhan CN, Savill J (2005) Resolution of inflammation: the beginning programs the end. Nat Immunol 6:1191–1197
17. Ware LB, Matthay MA (2000) The acute respiratory distress syndrome. N Engl J Med 342:1334–1349
18. Forel JM, Guervilly C, Hraiech S, Voillet F, Thomas G, Somma C, Secq V, Farnarier C, Payan MJ, Donati SY, Perrin G, Trousse D, Dizier S, Chiche L, Baumstarck K, Roch A, Papazian L, (2015) Type III procollagen is a reliable marker of ARDS-associated lung fibroproliferation. Intensive Care Med 41:1–11
19. Meduri GU, Kohler G, Headley S, Tolley E, Stentz F, Postlethwaite A (1995) Inflammatory cytokines in the BAL of patients with ARDS. Persistent elevation over time predicts poor outcome. Chest 108:1303–1314
20. Sinclair SE, Bijoy J, Golden E, Carratu P, Umberger R, Meduri GU (2006) Interleukin-8 and soluble intercellular adhesion molecule-1 during acute respiratory distress syndrome and in response to prolonged methylprednisolone treatment. Minerva Pneumologica 45:93–104